TScan's multiplexed TCR-T targeting both Mage and Prame simultaneously appears well thought out / researched. ( Nice presentations and slides).
Targeting the heterogeneity aspects ( for me i think of that as cancer dark matter) means thinking ahead to the mutations and stopping the cancer metastasis.
BMS is in deep over at IMTX, if i recall correctly Novartis deal with TCRX expires soon, if results come in decent i could see BMS interested here, imo.
TCRX is hard to read stock wise, undervalued imo, results at ASH might attract more respect.
TCRX management - upper echelon, imo.
News 
Market Data 
Discover 
